This article, written in response to receiving the academic conference award from the 72nd annual meeting of the Japanese society of allergology, reviews the author's research on allergic conjunctivitis, discusses its significance, and outlines future research directions.Previously, we reported that repeated topical application of pollen to the conjunctiva without prior systemic sensitization induced eosinophilic conjunctivitis and found that particulate matters like pollen shells were required for the development of local ocular allergy. To track the localization of antigens, we administered fluorescently labeled protein antigen to mouse conjunctiva together with pollen shells. Histological examination revealed that goblet cell associated antigen passages (GAPs) were rapidly formed upon stimulation of pollen shells. The antigen acquisition by the cells in the stroma was highly correlated with GAP formation.Kinetic experiments revealed that rapid antigen transport through GAPs played an important role in the development of the allergic conjunctivitis. Furthermore, topical anesthetics and electric ablation of the trigeminal nerve suppressed the pollen shell-stimulated GAP formation and antigen uptake in the conjunctiva. These results indicated that the pollen shell stimuli induced the GAP formation through a nerve-goblet cell association, which contributed to the development of allergic conjunctivitis.
{"title":"[THE SENSORY NERVOUS SYSTEM MEDIATES INDUCTION OF GOBLET CELL-ASSOCIATED ANTIGEN PASSAGE STIMULATED BY PARTICULATE MATTERS].","authors":"Meiko Kimura, Tomoaki Ando, Nobuyuki Ebihara, Jiro Kitaura","doi":"10.15036/arerugi.74.263","DOIUrl":"10.15036/arerugi.74.263","url":null,"abstract":"<p><p>This article, written in response to receiving the academic conference award from the 72nd annual meeting of the Japanese society of allergology, reviews the author's research on allergic conjunctivitis, discusses its significance, and outlines future research directions.Previously, we reported that repeated topical application of pollen to the conjunctiva without prior systemic sensitization induced eosinophilic conjunctivitis and found that particulate matters like pollen shells were required for the development of local ocular allergy. To track the localization of antigens, we administered fluorescently labeled protein antigen to mouse conjunctiva together with pollen shells. Histological examination revealed that goblet cell associated antigen passages (GAPs) were rapidly formed upon stimulation of pollen shells. The antigen acquisition by the cells in the stroma was highly correlated with GAP formation.Kinetic experiments revealed that rapid antigen transport through GAPs played an important role in the development of the allergic conjunctivitis. Furthermore, topical anesthetics and electric ablation of the trigeminal nerve suppressed the pollen shell-stimulated GAP formation and antigen uptake in the conjunctiva. These results indicated that the pollen shell stimuli induced the GAP formation through a nerve-goblet cell association, which contributed to the development of allergic conjunctivitis.</p>","PeriodicalId":35521,"journal":{"name":"Japanese Journal of Allergology","volume":"74 5","pages":"263-270"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.15036/arerugi.74.s123
{"title":"[Chairman's Special Program].","authors":"","doi":"10.15036/arerugi.74.s123","DOIUrl":"https://doi.org/10.15036/arerugi.74.s123","url":null,"abstract":"","PeriodicalId":35521,"journal":{"name":"Japanese Journal of Allergology","volume":"74 Supple","pages":"s123-s125"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Ensuring safe COVID-19 vaccination for patients with allergies is crucial for managing the pandemic. This study aimed to retrospectively investigate the frequency and safety of immediate allergic reactions in high-risk patients who received the Pfizer-BioNTech COVID-19 vaccine at our institution. The study was approved by Showa University Research Ethics Review Board (Approval number: 21-113-B).
Methods: In this retrospective cohort study conducted from June 2021 to December 2021, we included patients at a high risk for anaphylaxis who were vaccinated at our hospital. Subjects were patients who were at high risk of developing immediate allergy after vaccination, whose administration was considered unsafe at the local vaccination site, and who were requested by the local medical association or hospital. COVID-19 vaccine from Pfizer-BioNTech was administered in our outpatient clinic under the supervision of an allergist.
Results: 49 high-risk patients received the COVID-19 vaccine; five had anaphylaxis-like reactions, and one was diagnosed with anaphylaxis.
Conclusion: The rate of allergic reactions to the COVID-19 vaccine (2.0%) was higher in patients with a history of high-risk allergies than in the general population. However, no severe anaphylaxis cases were observed, suggesting that with careful pre-evaluation and appropriate medical supervision, vaccination may be feasible even for high-risk individuals. Nonetheless, caution is warranted due to the increased incidence of anaphylaxis compared to the general population.
{"title":"[TO INCREASE COVID-19 VACCINATION RATE OF SEVERELY ALLERGIC PATIENTS UTILIZE REGIONAL COLLABORATION].","authors":"Makoto Nojo, Shintaro Suzuki, Tomoki Uno, Yoshitaka Uchida, Hatsuko Mikuni, Yuto Miyata, Akihiko Tanaka, Hironori Sagara","doi":"10.15036/arerugi.74.206","DOIUrl":"https://doi.org/10.15036/arerugi.74.206","url":null,"abstract":"<p><strong>Background: </strong>Ensuring safe COVID-19 vaccination for patients with allergies is crucial for managing the pandemic. This study aimed to retrospectively investigate the frequency and safety of immediate allergic reactions in high-risk patients who received the Pfizer-BioNTech COVID-19 vaccine at our institution. The study was approved by Showa University Research Ethics Review Board (Approval number: 21-113-B).</p><p><strong>Methods: </strong>In this retrospective cohort study conducted from June 2021 to December 2021, we included patients at a high risk for anaphylaxis who were vaccinated at our hospital. Subjects were patients who were at high risk of developing immediate allergy after vaccination, whose administration was considered unsafe at the local vaccination site, and who were requested by the local medical association or hospital. COVID-19 vaccine from Pfizer-BioNTech was administered in our outpatient clinic under the supervision of an allergist.</p><p><strong>Results: </strong>49 high-risk patients received the COVID-19 vaccine; five had anaphylaxis-like reactions, and one was diagnosed with anaphylaxis.</p><p><strong>Conclusion: </strong>The rate of allergic reactions to the COVID-19 vaccine (2.0%) was higher in patients with a history of high-risk allergies than in the general population. However, no severe anaphylaxis cases were observed, suggesting that with careful pre-evaluation and appropriate medical supervision, vaccination may be feasible even for high-risk individuals. Nonetheless, caution is warranted due to the increased incidence of anaphylaxis compared to the general population.</p>","PeriodicalId":35521,"journal":{"name":"Japanese Journal of Allergology","volume":"74 4","pages":"206-211"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144822772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号